Personalized diet study for women with advanced breast or gynecologic cancer
Part of Cancer, Skin clinical trials.
This study tests whether a personalized dietary plan can help manage side effects and improve well-being in women with advanced breast or gynecologic cancer who are receiving antibody-drug conjugate (ADC) therapy. ADCs are a type of targeted cancer treatment that delivers chemotherapy directly to cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have advanced (stage IV or unresectable stage III) breast, ovarian, cervical, uterine, endometrial, fallopian tube, vaginal, or vulvar cancer.
- You have already received your first cycle of an ADC treatment.
- You are in generally good physical condition (able to care for yourself and up and about more than 50% of waking hours).
- You do not have type 1 diabetes, severe digestive or metabolic disorders, or severe kidney or liver problems.
- You are willing and able to use a smartphone app and a wearable device for the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people with advanced breast, bladder, lung, or stomach cancer who are about to start treatment with a type of targeted therapy called an antibody-drug conjugate (ADC). The trial will collect tumor samples and blood to understand how cancers become resistant to these drugs and to find better ways to predict treatment success.
This study looks at whether giving a different antibody-drug conjugate (ADC) after a previous one can help people with advanced or metastatic breast cancer. It aims to find new options for patients who have already had ADC treatment.
This study tests a new type of targeted therapy called an antibody-drug conjugate (ADC) for advanced breast cancer that is hormone-receptor-positive and HER2-negative. It is for people whose cancer has progressed after CDK4/6 inhibitor treatment, and may offer a new option to slow tumor growth.
This trial is testing the best time to give an antibody-drug conjugate (ADC) to people with advanced breast cancer that is HER2-negative. It aims to find out if giving this treatment after first chemotherapy fails can help slow the cancer's growth.
This study tests different treatments tailored to your cancer's biology. It aims to find which therapy might work best for you, potentially improving outcomes. You'd receive one of the study drugs, with close monitoring and support.
This trial uses information from a biopsy of your tumor to help choose the best treatment for advanced or metastatic hormone receptor-positive breast cancer. The goal is to find a therapy that works better for you.
Hear when a new Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.